PillSeek

Professional Information — Cefpodoxime Proxetil Cefpodoxime Proxetil 200 Mg 1

Full FDA prescribing details for healthcare professionals.

Last updated · May 16, 2026Source: DailyMed ↗
On this page
Highlights of Prescribing InformationRevised: Aug 11, 2025

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications and Usage

Cefpodoxime Proxetil Tablets are indicated for the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of Staphylococcus pseudintermediusStaphylococcus aureus, Streptococcus canis (group G, ß hemolytic), Escherichia coli, Pasteurella multocida, and Proteus mirabilis.

Dosage and Administration

Dose range

The dose range of Cefpodoxime Proxetil Tablets is 5-10 mg/kg (2.3-4.5 mg/lb) body weight, administered orally, once a day. The dose may be given with or without food. The determination of dosage for any particular patient must take into consideration such factors as the severity and nature of the infection, the susceptibility of the causative organisms, and the integrity of the patient's host-defense mechanisms. Obtain a sample of the pathogenic organism for culture and sensitivity testing prior to beginning antimicrobial therapy. Once results become available, continue with appropriate therapy.

Duration

Cefpodoxime Proxetil Tablets should be administered once daily for 5-7 days or for 2-3 days beyond the cessation of clinical signs, up to a maximum of 28 days. Treatment of acute infections should not be continued for more than 3-4 days if no response to therapy is seen.

Dosing Charts

For daily oral administration of Cefpodoxime Proxetil Tablets at 5 mg/kg (Table 1) and 10 mg/kg (Table 2).

Table 1. Dose Table for Cefpodoxime Proxetil Tablets at 5 mg/kg Total Daily Dosage


Weight of Dog (lbs)

Daily Dose 

22

44

66

88

132

No. of 100 mg tablets

0.5

1

1.5

 

1

No. of 200 mg tablets

 

 

 

1

1

Weight of Dog (kgs)

Daily Dose

10

20

30

40

60

No. of 100 mg tablets

0.5 

1

1.5 

 

1

No. of 200 mg tablets

 

 

 

1

1

Table 2. Dose Table for Cefpodoxime Proxetil Tablets at 10 mg/kg Total Daily Dosage



Weight of Dog (lbs) 

Daily Dose

11 

22 

44 

66 

88 

132

No. of 100 mg tablets

0.5


 

1

 

 

No. of 200 mg tablets

1

1

2

3


Weight of Dog (kgs) 

Daily Dose 


10 

20 

30 

40 

60

No. of 100 mg tablets

0.5 

1

 


 

 

No. of 200 mg tablets

1



3

Contraindications

Cefpodoxime proxetil is contraindicated in dogs with known allergy to cefpodoxime or to the ß-lactam (penicillins and cephalosporins) group of antibiotics.

Adverse Reactions

A total of 216 dogs of various breeds and ages ranging from 2 months to 15 years were included in the field study safety analysis. The following table shows the number of dogs displaying each clinical observation.

Table 3. Abnormal Health Findings in the U.S. Field Study*



Clinical Observation

cefpodoxime proxetil tablets (n=118) 

Active Control (n=98)

Vomiting

2

4

Diarrhea

1

1

Increased water drinking

0

2

Decreased appetite

1

1

*Dogs may have experienced more than one of the observations during the study.


Description

Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic cephalosporin antibiotic. The chemical name is: (+/-)-1-Hydroxyethyl(+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl) glyoxylamido]-3-methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, 72-(Z)- (O-methyloxime), isopropyl carbonate (ester) [87239-81-4].

Cefpodoxime proxetil Chemical Structure:

Cefpodoxime proxetil is a prodrug; its active metabolite is cefpodoxime. All doses of Cefpodoxime Proxetil Tablets are expressed in terms of the active cefpodoxime moiety. Cefpodoxime Proxetil Tablets are available as:

100 mg Tablet, each red-colored, oval-shaped, film-coated, scored tablet contains cefpodoxime proxetil equivalent to 100 mg of cefpodoxime.

200 mg Tablet, each orange-colored, oblong-shaped, film-coated, scored tablet contains cefpodoxime proxetil equivalent to 200 mg of cefpodoxime.

structure

Clinical Pharmacology

Pharmacokinetics/Pharmacodynamics

Cefpodoxime proxetil is a prodrug that is absorbed from and de-esterified in the gastrointestinal tract to its active metabolite, cefpodoxime. Following oral administration to fasting Beagles, oral bioavailability was 63.1 ± 5.3%.

Figure 1. Canine Plasma Concentration of Cefpodoxime After a Single Oral Dose of 10 mg/kg cefpodoxime proxetil tablets

Cefpodoxime is distributed in the body with an apparent volume of distribution of 151 ± 27 mL/kg. Like other β-lactam antibiotics, cefpodoxime is eliminated from the body primarily in the urine, with an apparent elimination half-life of approximately 5-6 hours after oral administration. This is similar to the 4.7 hour apparent elimination half-life observed after intravenous dosing. Following intravenous administration of 10 mg/kg, the average total body clearance (CIB) was 22.7 ± 4.19 mL/hr/kg.

Table 4. Summary of Pharmacokinetic Parameters Obtained after a Single Oral Dose of 10 mg Cefpodoxime/kg BW, Administered as a Tablet


PK Parameter 

Unit 

Tablet (SD)

AUC0-∞

mcg•hr/mL

145 (77.6) 

AUC0-LOQ 

mcg•hr/mL

142 (77.5) 

Maximum concentration (Cmax)

mcg/mL 

16.4 (11.8)

Terminal plasma elimination half-life (t1/2,Z)

hr 

5.61 (1.15)

Time of maximum concentration (tmax)

hr 

2.21 (0.542)

Mean residence time (MRT0-∞)

hr 

9.21 (1.97) 

Microbiology

Like other β-lactam antibiotics, cefpodoxime exerts its inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalently binding to the penicillin-binding proteins (PBPs) (i.e. transpeptidase and/or carboxypeptidase), which are essential for synthesis of the bacterial cell wall. Therefore, cefpodoxime is bactericidal. Cefpodoxime is stable in the presence of many common β-lactamase enzymes. As a result, many organisms resistant to other β-lactam antibiotics (penicillins and some cephalosporins) due to the production of β-lactamases may be susceptible to cefpodoxime.

Cefpodoxime has a broad spectrum of clinically useful antibacterial activity that includes staphylococci, streptococci, and Gram-negative species (including Pasteurella, Escherichia, and Proteus). The compound is not active against most obligate anaerobes, Pseudomonas spp., or enterococci. The minimum inhibitory concentrations (MICs) for cefpodoxime against Gram-positive and Gram-negative pathogens isolated from canine skin infections (wounds and abscesses) in a 2002 U.S. field study are presented in Table 5. All MICs were determined in accordance with the National Committee for Clinical Laboratory Standards (NCCLS). Appropriate quality control (QC) ranges for in vitro susceptibility testing are presented in Table 6.

Table 5. Cefpodoxime Minimum Inhibitory Concentration Values (mcg/mL) from a 2002  Field Study Evaluating Skin Infections (wounds and abscesses) of Canines in the United States.


Organism*

# of Isolates

MIC50

MIC90

Range

Staphylococcus pseudintermedius

118

0.12

0.50

0.12->32.0

Streptococcus canis (group G, β hemolytic)

33

≤0.03

≤0.03

≤0.03

Escherichia coli 

41

0.25

0.50

0.12->32.0

Pasteurella multocida 

32

≤0.03

≤0.03

≤0.03-0.12

Proteus mirabilis

14

≤0.03

0.06

≤0.03-0.06

Staphylococcus aureus 

19

2.0

2.0

0.12-2.0

* Veterinary specific interpretive criteria have not been established for the above listed canine pathogens by the NCCLS at this time.

 No Range, all isolates yielded the same value.


Table 6. Acceptable Quality Control Ranges for Cefpodoxime


QC ATCC strain

KB Disk Diffusion Method

Broth Micro-dilution Method

Drug concentration

Zone diameter

MIC

Escherichia coli 25922

10 mcg

23-28 mm*

0.25-1 mcg/mL*

Staphylococcus aureus 25923

10 mcg

19-25 mm*

 

Staphylococcus aureus 29213

 

 

1-8 mcg/mL*

Streptococcus pneumoniae 49619

10 mcg

28-34 mm

0.03-0.12 mcg/mL

*These ranges are for quality control strains used to monitor accuracy of minimum inhibitory concentrations (MICs) of non-fastidious organisms using cation-adjusted Mueller-Hinton agar or broth medium. The dilution range should encompass the QC ranges of these strains in the broth micro-dilution method.

These ranges are for quality control strains used to monitor accuracy of minimum inhibitory concentrations (MICs) of fastidious organisms. When susceptibility testing is performed for Streptococcus canis (group G, β hemolytic), Streptococcus pneumoniae ATCC 49619 should be included as a QC strain in the presence of 5% lysed sheep blood (KB disk diffusion method) or 2.5% lysed horse blood (broth micro-dilution method).

graph

How Supplied / Storage and Handling

Cefpodoxime Proxetil Tablets are available in the following strengths (cefpodoxime equivalent), colors, and sizes:


100 mg (Red-colored, oval-shaped, film-coated tablet, debossed with "F" & "3" on either side of score line on one side of tablets and "1" & "00" on either side of score line on other side of the tablet.)


Bottles of 100

NDC 11695-7040-2

Bottles of 250

NDC 11695-7040-1

200 mg (Orange-colored, oblong-shaped, film-coated tablet, debossed with "F" & "3" on either side of score line on one side of tablets and "2" & "00" on either side of score line on other side of the tablet.)


Bottles of 100

NDC 11695-7041-2

Bottles of 250

NDC 11695-7041-1

Sources

RxCUI: 309078

NDC: 658620096

Last fetched: May 16, 2026

Source: DailyMed ↗

⚠️ Disclaimer

This information is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.